Revenue

Marex's strategic investment in Digital Prime Technologies isn't just a deal; it's a blueprint for bringing Wall Street's rigor to digital asset lending.

AB InBev's new global campaign isn't just marketing. It's a strategic play backed by strong financials and data showing beer's resilient dominance.

AIR Global's plan to buy back a huge chunk of its shares raises key questions. Is it a bold move to boost value or a complex financial shuffle amid market headwinds?

As Ascentage Pharma preps its mid-year report, we look beyond the balance sheet at the strategic plays and clinical trials fueling its global oncology ambitions.

Lifeward's pilot program with Ottobock Care isn't just a deal; it’s a strategic blueprint for scaling advanced medical tech in a new era of reimbursement.

XPEL smashes Q2 estimates with record revenue, fueled by explosive China growth. But a costly manufacturing pivot tests its long-term strategy.

CDW announces CFO Albert Miralles will retire in 2027, initiating a carefully planned succession amid strong financial performance and a dynamic IT market.

With its sixth straight quarter of double-digit growth, Extreme Networks leverages its AI platform and Wi-Fi 7 leadership to win major deals and reshape enterprise networking.

Nacon's path out of bankruptcy is now tied to its parent, Bigben Interactive. But the lifeline comes with a stark warning of 'significant dilution' for shareholders.

CDW's Q2 earnings beat expectations with a 10% sales jump, thanks to AI and cloud demand. But a dip in gross margins and restructuring costs spooked the market.

Valvoline's stellar Q3 results reveal a masterclass in corporate strategy, turning rising costs into record profits. But is this a sustainable model?

Acacia Research's Q2 results show a massive revenue jump from a patent deal, but a $31M write-down reveals the risks in its diversified strategy.

A quiet South Korean biotech is shaking up the drug delivery landscape. Alteogen's latest deal signals a major shift as Big Pharma races to make treatments better.

Shake Shack's Q2 results show impressive revenue growth and customer traffic, yet profits are shrinking. A deep dive reveals a company grappling with the high cost of expansion and inflation.

As J.M. Smucker prepares for a pivotal earnings call, a deeper look reveals a company balancing legacy brands with high-growth bets in a shifting market.

Eton Pharmaceuticals' new deal for ASN-001 is more than a pipeline buy; it's a calculated maneuver to capture the entire infantile hemangioma treatment space.

A revenue dip masks a calculated pivot. UTHR is betting its future not just on new drugs, but on a revolutionary plan to manufacture human organs.

Pyxus International's Q1 sales fell, but a forensic look reveals a firm mastering a flooded market, boosting margins and shoring up its financial foundations.

Criteo's Q2 results reveal a company under severe pressure, with net income plummeting 49%. But behind the grim numbers, a high-stakes pivot to AI and a US redomiciliation is underway.

As Stella-Jones reports Q2 earnings, investors watch if robust demand for utility and rail products can offset residential market volatility and cost pressures.